Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

sangysmith Feb. 20 at 12:46 PM

$PMN Key Clinical Milestones (2026) Q2 2026: Blinded 6-Month Interim Data from PRECISE-AD (Phase 1b) Q4 2026: Final 12-Month Top-Line Results from PRECISE-AD Possibility of direct proceed to PH3 based on recent CEO interview and FDA easing the testing requirements

0 · Reply

ChartMenace Feb. 19 at 5:35 PM

$NIVF $MBRX $KXIN $PMN +

0 · Reply

Sunny3999 Feb. 18 at 5:22 PM

$PMN NEXT STOP $50 $ABC $AMZN $COST $WMT

0 · Reply

Sunny3999 Feb. 18 at 5:21 PM

$PMN NEXT STOP $50 $BAC $C $GS $MS

0 · Reply

Sunny3999 Feb. 18 at 5:20 PM

$PMN NEXT STOP $50 $ACET $PAVM $PMNT $RVPH

0 · Reply

Sunny3999 Feb. 18 at 5:19 PM

$PMN NEXT STOP $50 $CAH $CI $COR $MCK

0 · Reply

Sunny3999 Feb. 18 at 5:18 PM

$PMN NEXT STOP $50 $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Feb. 18 at 5:17 PM

$PMN NEXT STOP $50 $C $RY $SCHF $WFC

0 · Reply

Sunny3999 Feb. 18 at 5:16 PM

$PMN NEXT STOP $50 $AAPL $GOOG $META $MSFT

0 · Reply

Sunny3999 Feb. 18 at 5:15 PM

$PMN NEXT STOP $50 $CNC $CVS $UNH $WBA

1 · Reply

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 30, 2026, 8:00 AM EST - 22 days ago

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Dec 18, 2025, 7:30 AM EST - 2 months ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 10, 2025, 7:30 AM EST - 2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 1, 2025, 7:30 AM EST - 2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:00 AM EST - 2 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 3 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Nov 12, 2025, 7:00 AM EST - 3 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 3, 2025, 4:05 PM EST - 3 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 4 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 3, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 7 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 7 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 7 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 10 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 2 years ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

sangysmith Feb. 20 at 12:46 PM

0 · Reply

ChartMenace Feb. 19 at 5:35 PM

$NIVF $MBRX $KXIN $PMN +

0 · Reply

Sunny3999 Feb. 18 at 5:22 PM

$PMN NEXT STOP $50 $ABC $AMZN $COST $WMT

0 · Reply

Sunny3999 Feb. 18 at 5:21 PM

$PMN NEXT STOP $50 $BAC $C $GS $MS

0 · Reply

Sunny3999 Feb. 18 at 5:20 PM

$PMN NEXT STOP $50 $ACET $PAVM $PMNT $RVPH

0 · Reply

Sunny3999 Feb. 18 at 5:19 PM

$PMN NEXT STOP $50 $CAH $CI $COR $MCK

0 · Reply

Sunny3999 Feb. 18 at 5:18 PM

$PMN NEXT STOP $50 $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Feb. 18 at 5:17 PM

$PMN NEXT STOP $50 $C $RY $SCHF $WFC

0 · Reply

Sunny3999 Feb. 18 at 5:16 PM

$PMN NEXT STOP $50 $AAPL $GOOG $META $MSFT

0 · Reply

Sunny3999 Feb. 18 at 5:15 PM

$PMN NEXT STOP $50 $CNC $CVS $UNH $WBA

1 · Reply

Sunny3999 Feb. 18 at 5:14 PM

$PMN NEXT STOP $50 $HUM $MET $MSBI $UNH

0 · Reply

Sunny3999 Feb. 18 at 5:14 PM

$PMN NEXT STOP $50

0 · Reply

Sunny3999 Feb. 18 at 5:12 PM

$PMN NEXT STOP $50 $ABBV $AMGN $CELG $GILD

0 · Reply

Sunny3999 Feb. 18 at 5:11 PM

$PMN NEXT STOP $50 $JNJ $LLY $PFE $REGN

0 · Reply

Stock__Hunter Feb. 18 at 3:50 PM

$PMN keeps on trucking

0 · Reply

ChartMenace Feb. 18 at 12:35 PM

$KXIN $PMN $PLRZ $IVF ]

0 · Reply

Blueknoser Feb. 17 at 6:51 PM

$PMN it's still plenty early to get in.....!

0 · Reply

ChartMenace Feb. 17 at 6:18 PM

$KXIN $PMN $PLRZ $IVF 0

0 · Reply

Blueknoser Feb. 17 at 5:03 PM

$PMN In the last press release, the Mr. Neil Warma used the phrases, "Watershed year and transformative year", potentially 80 - 90% of biomarker results in and perhaps 75% of clinical patients results obvious to staff; when you consider employees and the Board of Directors are all buying copious amounts of shares..... the CEO was super confident in the latest Fireside Chat - all this leads little doubt about the results of the clinical trial. PMN 310 will potentially be the next best treatment for Alzheimer's!! Wow!! This is going to explode!!!

0 · Reply

Stock__Hunter Feb. 17 at 2:48 PM

$PMN .

0 · Reply

PortfolioQuasar Feb. 17 at 2:29 PM

$PMN ProMIS Neurosciences; early-stage neurodegenerative pipeline; high clinical risk.

0 · Reply

ChartMenace Feb. 17 at 1:28 PM

$MBRX $KXIN $PMN ~

0 · Reply

Market Cap	34.78M
Revenue (ttm)	0.00
Net Income (ttm)	2.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	33,100
Avg Vol	192,568
Day's Range	N/A - N/A
Shares Out	2.15M
Stochastic %K	79%
Beta	-0.08
Analysts	Strong Sell
Price Target	$34.38